Randomised Control Trial of Dexmedetomidine and Magnesium Sulfate as an Adjuvant to Ropivacaine in Supraclavicular Brachial Plexus Block
DOI:
https://doi.org/10.37506/ijocm.v7i2.311Keywords:
Dexmedetomidine, Magnesium sulfate, Supraclavicular block, Ropivacaine.Abstract
Background
Several adjuvants potentiate peripheral nerve block. We studied effects of adding magnesium sulfate or dexmedetomidine to 20 ml 0.75% ropivacaine for supraclavicular brachial plexus block.
Materials and Method
80 patients were divided in four groups, which, in addition to ropivacaine, received: Group A- 1 ml normal saline, Group B- 125 mg magnesium sulfate, Group C- 250 mg magnesium sulfate, Group D- 1 ?g/kg dexmedetomidine.
Results
Duration of analgesia was significantly prolonged, onset of sensory and motor blockade was hastened and analgesic requirement was reduced in a dose responsive manner (for magnesium group), without causing clinically significant and unmanageable side effects. Intensity of potentiation was higher with dexmedetomidine than magnesium sulfate.
Conclusion
Magnesium sulfate potentiates supraclavicular block in a dose dependent manner. Potentiation by dexmedetomidine is greater than that by magnesium sulfate.
